1313517-77-9Relevant articles and documents
Selective and brain-permeable polo-like kinase-2 (Plk-2) inhibitors that reduce α-synuclein phosphorylation in rat brain
Aubele, Danielle L.,Hom, Roy K.,Adler, Marc,Galemmo, Robert A.,Bowers, Simeon,Truong, Anh P.,Pan, Hu,Beroza, Paul,Neitz, R. Jeffrey,Yao, Nanhua,Lin, May,Tonn, George,Zhang, Heather,Bova, Michael P.,Ren, Zhao,Tam, Danny,Ruslim, Lany,Baker, Jeanne,Diep, Linnea,Fitzgerald, Kent,Hoffman, Jennifer,Motter, Ruth,Fauss, Donald,Tanaka, Pearl,Dappen, Michael,Jagodzinski, Jacek,Chan, Wayman,Konradi, Andrei W.,Latimer, Lee,Zhu, Yong L.,Sham, Hing L.,Anderson, John P.,Bergeron, Marcelle,Artis, Dean R.
supporting information, p. 1295 - 1313 (2013/08/23)
Polo-like kinase-2 (Plk-2) has been implicated as the dominant kinase involved in the phosphorylation of α-synuclein in Lewy bodies, which are one of the hallmarks of Parkinson's disease neuropathology. Potent, selective, brain-penetrant inhibitors of Plk
